HC
TEVA icon

Hampstead Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Hampstead Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-110,000
Closed -$3.65M – 34
2017
Q2 		$3.65M Hold
110,000
– – 3.6% 8
2017
Q1 		$3.53M Buy
110,000
+35,000
+47% +$1.19M 3.65% 9
2016
Q4 		$2.72M Buy
+75,000
New +$2.99M 2.88% 22

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Hampstead Capital's TEVA Position: Q3 2017 in Review

Hampstead Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 110,000 shares — an estimated $3.65M sold.

Hampstead Capital first reported a position in TEVA in Q4 2016 and held it in 3 quarters. The position peaked at $3.65M in Q2 2017. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

  • Hampstead Capital reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Hampstead Capital sold 110,000 Teva Pharmaceuticals shares in Q3 2017, an estimated $3.65M.
  • Hampstead Capital first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Hampstead Capital's Teva Pharmaceuticals position peaked at $3.65M in Q2 2017.
  • 535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Hampstead Capital's 13F filing for Q3 2017, filed 15 Nov 2017.